In the context of CAR-T cell immunotherapy, HLA-G has been targeted by engineered CAR T cells, aiming to eliminate HLA-G-expressing tumor cells and thereby overcome its immune checkpoint function (56), and is currently under investigation in a Phase I/II clinical trial (57), among other therapeutic approaches (Table 1). This evidence concerns the gene HLA-G and neoplasm.